

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## **Nucleosides, Nucleotides and Nucleic Acids**

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## **Phosphorothioate Analogs OF 2-5A: Activation / Inhibition of Rnase L and Inhibition of HIV-1 Reverse Transcriftase**

Robert J. Suhadolnik<sup>a</sup>; Bernard Lebleu<sup>a</sup>; Wolfgang Pfliederer<sup>a</sup>; Ramamurthy Charubala<sup>a</sup>; David C. Montefiori<sup>a</sup>; William M. Mitchell<sup>a</sup>; Robert W. Sobol Jr.<sup>a</sup>; Shi Wu Li<sup>a</sup>; Katalin Kariko<sup>a</sup>; Nancy L. Reichenbach<sup>a</sup>

<sup>a</sup> Temple University School of Medicine, Philadelphia, Pennsylvania, USA; Université de Montpellier, Montpellier, France; Universität Konstanz, Konstanz, Germany; Vanderbilt University School of Medicine, Nashville, Tennessee, USA

**To cite this Article** Suhadolnik, Robert J. , Lebleu, Bernard , Pfliederer, Wolfgang , Charubala, Ramamurthy , Montefiori, David C. , Mitchell, William M. , Sobol Jr., Robert W. , Li, Shi Wu , Kariko, Katalin and Reichenbach, Nancy L.(1989) 'Phosphorothioate Analogs OF 2-5A: Activation / Inhibition of Rnase L and Inhibition of HIV-1 Reverse Transcriftase', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 987 — 990

**To link to this Article:** DOI: 10.1080/07328318908054260

**URL:** <http://dx.doi.org/10.1080/07328318908054260>

**PLEASE SCROLL DOWN FOR ARTICLE**

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.


The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

PHOSPHOROTHIOATE ANALOGS OF 2-5A: ACTIVATION / INHIBITION OF RNASE L AND INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE


Robert J. Suhadolnik, Bernard Lebleu, Wolfgang Pfleiderer, Ramamurthy Charubala, David C. Montefiori, William M. Mitchell, Robert W. Sobol, Jr., Shi Wu Li, Katalin Kariko and Nancy L. Reichenbach

Temple University School of Medicine, Philadelphia, Pennsylvania, USA; Université de Montpellier, Montpellier, France; Universität Konstanz, Konstanz, Germany; Vanderbilt University School of Medicine, Nashville, Tennessee, USA


Chemically and enzymatically synthesized diastereomeric 2',5'-phosphorothioate dimer, trimer and tetramer cores and their 5'-mono- and triphosphates demonstrate marked differences in their ability to bind to and activate RNase L from L929 cell extracts in radiobinding, core-cellulose and rRNA cleavage assays<sup>1,2</sup> (Fig. 1). These are the first 2-5A cores that are able to bind to and activate RNase L. The enzymatically synthesized 2',5'-phosphorothioate dimer and trimer 5'-triphosphates can also bind to and activate RNase L<sup>1</sup>.



**Figure 1.** Structures of four diastereomers of the 2',5'-phosphorothioate tetramer cores.



**Figure 2.** Ribosomal RNA cleavage assay with 2',5'-phosphorothioate tetramer 5'-monophosphates. L929 cell extracts were incubated in the absence (lane 2) or the presence of  $p_3A_4$  at  $10^{-8}$  M (lane 1), pRpSpSp at  $10^{-8}$  M (lane 3), pSpRpRp at  $10^{-8}$  M (lane 4), pRpRpRp at  $10^{-8}$  M (lane 5), or pSpSpSp at  $10^{-3}$  M (lane 6). The positions of 28S and 18S rRNA are shown. The arrows indicate the positions of the well-characterized specific cleavage products (SCP) of RNase L.



**Figure 3.** Inhibition of cellular protein synthesis by the 2',5'-phosphorothioate tetramer 5'-monophosphates in intact L929 cells. The procedure for the calcium phosphate coprecipitation technique was as described. Control cultures were treated with calcium phosphate but no oligonucleotides. The incorporation of [<sup>3</sup>H]leucine in control cultures was taken as 100% (1500 dpm). p<sub>3</sub>A<sub>4</sub> (●); pRpSpSp (Δ); pSpSpSp (▼).

**Table 1.** Antiviral Effects of 2-5A<sub>4</sub> oxred and pSpSp in Intact HeLa Cells

First injection	Second injection	VSV Yield (pfu/100 cells)	log (pfu/100 cells)
H <sub>2</sub> O	H <sub>2</sub> O	2.5 x 10 <sup>4</sup>	4.39
H <sub>2</sub> O	1 μM 2-5A <sub>4</sub> oxred	1.3 x 10 <sup>2</sup>	2.11
H <sub>2</sub> O	100 nM 2-5A <sub>4</sub> oxred	2.2 x 10 <sup>3</sup>	3.30
1 μM pSpSp	H <sub>2</sub> O	7 x 10 <sup>3</sup>	3.80
1 μM pSpSp	1 μM 2-5A <sub>4</sub> oxred	8.4 x 10 <sup>3</sup>	3.90
1 μM pSpSp	100 nM 2-5A <sub>4</sub> oxred	2.2 x 10 <sup>4</sup>	4.30
1 μM pSpSp + 1 μM 2-5A <sub>4</sub> oxred		8.4 x 10 <sup>3</sup>	3.90

One hundred HeLa cells were microinjected<sup>5</sup> with 0.5 pL each of 2-5A<sub>4</sub> oxred [3' modified 2-5A<sub>4</sub> which is more stable than authentic 2-5A<sub>4</sub>] or pSpSp at the indicated concentrations. One hour later, cells were challenged with VSV at a m.o.i. of 10 and the virus titers were determined 18 hours later by an end-point on L929 cells.

**Binding and Activation of RNase L.** The chemically synthesized 2',5'-phosphorothioate tetramer cores (i.e., RpRpRp, SpRpRp, RpSpSp and SpSpSp) and corresponding 5'-monophosphates bind to RNase L in L929 cell extracts as determined by radiobinding assay<sup>3</sup>. Activation of RNase L by the 2',5'-phosphorothioate tetramer cores and 5'-monophosphates was measured in rRNA cleavage assays with L929 cell extracts<sup>2</sup>. The RpRpRp, SpRpRp and RpSpSp tetramer cores (1 x 10<sup>-7</sup> M) activate RNase L to cleave 28S and 18S rRNA to specific cleavage products (SCP). The SpSpSp tetramer core (1 x 10<sup>-3</sup> M) does not activate RNase L. The pRpRpRp, pSpRpSp and pRpSpSp (1 x 10<sup>-8</sup> M) activate RNase L to cleave 28S and 18S rRNA (Fig. 2, lanes 2-4). However, the pSpSpSp tetramer (1 x 10<sup>-5</sup> M) does not activate RNase L (Fig. 2, lane 5).

**Inhibition of Cellular Protein Synthesis.** Studies were done with intact cells to determine whether the *in vitro* data could be extrapolated to the inhibition of protein synthesis in the intact cell. This was accomplished by the calcium phosphate coprecipitation technique<sup>4</sup>. The pRpSpSp but not the pSpSpSp tetramer 5'-monophosphate inhibited cellular protein synthesis in a dose-dependent manner (Fig. 3). These data indicate that the inhibition of protein synthesis proceeds via the activation of RNase L.

**Antiviral Effects in Intact Cells.** A 2-5A molecule capable of selectively inhibiting RNase L activation has been an elusive goal as a means to precisely assess the involvement of RNase L in the interferon-induced antiviral and antiproliferative cascade. The demonstrated ability of the pSpSp analog to bind to but not activate RNase L, plus its significantly increased stability<sup>2</sup>, makes it most attractive for *in vivo* studies. Microinjection of the pSpSp analog into the cytoplasm of HeLa cells did not inhibit multiplication of VSV at concentrations as high as  $10^{-6}$  M, whereas 100 nM 2-5A<sub>oxred</sub> exhibited a substantial antiviral effect (Table 1). When injected prior to 2-5A<sub>oxred</sub>, the pSpSp analog inhibits the antiviral effect of 2-5A<sub>oxred</sub>.

**Inhibition of HIV-1 Reverse Transcriptase and Anti-HIV Activity.** The phosphorothioate analogs of 2-5A inhibit human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) in viral lysates and inhibit replication of HIV-1 in MT-2 cells<sup>6</sup>. HIV-1 RT was not inhibited by authentic 2',5'-adenylate trimer core (A<sub>3</sub>) or 5'-triphosphate (p<sub>3</sub>A<sub>3</sub>) at 0.25 - 256  $\mu$ M. In contrast, a concentration-dependent inhibition of HIV-1 RT was observed with the 2',5'-phosphorothioate tetramer 5'-monophosphates (30 - 58% inhibition at 2.5  $\mu$ M). The enzymatically synthesized RpRp trimer 5'-triphosphate was the most potent inhibitor of HIV-1 RT (50% inhibition at 0.5  $\mu$ M). The pRpSpSp analog was shown to have antiviral activity against HIV-1 in an *in vitro* MT-2 cell microtiter infection assay<sup>6</sup>. This inhibition of RT and HIV-1 replication may represent a new and important role of 2',5'-oligoadenylate analogs in the control of retrovirus replication.

Supported in part by NIH research grant P01 CA29545.

#### REFERENCES

1. Kariko, K., Sobol, R.W., Jr., Suhadolnik L., Li, S.W., Reichenbach, N.L., Suhadolnik, R.J., Charubala, R. and Pflleiderer, W. (1987) *Biochemistry* **26**, 7127-7135.
2. Kariko, K., Li, S.W., Sobol, R. W., Jr., Suhadolnik, R.J., Charubala, R., and Pflleiderer, W. (1987) *Biochemistry* **26**, 7136-7142.
3. Knight, M., Wreschner, D.H., Silverman, R.H., and Kerr, I.M. (1981) *Methods Enzymol.* **79**, 216-227.
4. Lee, C., and Suhadolnik, R.J. (1983) *FEBS Lett.* **157**, 205-209.
5. Bayard, B., Leserman, L.D., Bisbal, C., and Lebleu, B. (1985) *Eur. J. Biochem.* **151**, 319-325.
6. Montefiori, D. C., Sobol, R.W., Jr., Kariko, K., Li, S.W., Reichenbach, N.L., Suhadolnik, R.J., Charubala, R., Pflleiderer, W., Robinson, W.E., Jr., and Mitchell, W.M. (1988) *Science*, in press.